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USE OF PARTHENOLIDE DERIVATIVES AS 
ANTILEUKEMIC AND CYTOTOXIC 
AGENTS 
This application claims priority to provisional application 
60/486,171 ?led Jul. 11, 2003. 
FIELD OF INVENTION 
The present invention relates to methods for the structural 
modi?cation of the sesquiterpene lactone, parthenolide, and 
the use of these parthenolide derivatives in the treatment of 
carcinoma. More speci?cally, the invention relates to the 
methods to prepare structural analogs of the parent com 
pound, parthenolide, in order to obtain neW, pharmacologi 
cally active chemical entities With improved Water solubility 
characteristics, and to use them in the treatment of leukemias 
and other parental and multi-drug resistant human cancers. 
BACKGROUND OF THE INVENTION 
Sesquiterpene lactones are a group of secondary plant 
metabolites consisting of a 15-carbon structure containing 
an ot-methylene-y-butyrolactone moiety and other additional 
functional group(s). Over the last tWo to three decades, these 
terpenoids have received considerable attention due to the 
broad spectrum of their biological activities, to the plants 
Which produce them, and most importantly, because of their 
pharmacological effects in humans. About 4,000 of these 
terpenoids have been isolated and identi?ed, most of them in 
Asteraceae (Compositae, sun?ower family) (Schmidt, Curr 
Org. Chem. 1999, 3, 577*608). Some of these plants have 
been used for centuries in indigenous medical practices in 
different cultures WorldWide. 
Parthenolide (1) is a Germacrane sesquiterpene lactone 
With a unique structure. It has been isolated from several 
different species in Asteraceae (Compositae) family. The 
Well-knoWn FeverfeW (Tanacetum parthenium) is one of 
them. 
FeverfeW has been used to reduce fever and pain and in 
the treatment of migraine and rheumatoid arthritis (Heptin 
stall et al., ACS Symposium Series (1998), 691 (Phytomedi 
cines of Europe), 158*175.). The active component is par 
thenolide (1). Recently, it has been revealed that 
parthenolide (1) can induce tumor apoptosis by the inhibi 
tion of NF-KB activities (Cory et al., Anticancer Research 
2002, 22, 3805*9; Cory et al., Anticancer Research 2001, 
21, 3807*11; Gelfanov et al., Blood, 2000, 98, 2508*17; 
Kang et al, Brit. J. Pharmacol. 2002, 135, 1235*44; Song et 
al., J. Asian. Nat. Prod. Res. 2001, 3, 285*91). 
Parthenolide (1) is a lipophilic, neutral lactone With loW 
polarity, and has a loW Water-solubility. This limits its 
further development as a therapeutic agent. According to the 
literature, the ot-methylene-y-butyrolactone moiety in par 
thenolide (1) appears to be the most important functionality 
for its anticancer activity (Wen et al, J. Biol. Chem. 2002, 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
277, 38954i38964) and modi?cation of this part of the 
molecule may cause loss of biological activity. Unfortu 
nately, derivatives obtained from the modi?cation of par 
thenolide (1 molecule at the 14-methyl group and at the 
1,10-carbon-carbon double bond result in loss of antileuke 
mic activity. 
SUMMARY OF THE INVENTION 
In accordance With the present invention, a novel class of 
nitrogen-containing parthenolide derivatives With antileuke 
mic activity is presented. 
The compounds of the invention are capable of killing 
leukemia cells. Therapeutic indications include leukemia 
and all human parental and/ or multi-drug resistant cancers; 
compounds for treating migraine and compounds for the 
treatment of in?ammation. 
The invention also provides a pharmaceutical composi 
tion comprising an effective amount of a parthenolide 
derivative compound, or a pharmaceutically acceptable salt 
thereof, in combination With a pharmaceutically acceptable 
diluent or carrier. 
The invention also provides a method of inhibiting cancer 
cell groWth and metastasis of cancer cells, comprising 
administering to a mammal a?licted With cancer, an amount 
of a parthenolide derivative compound, effective to inhibit 
the groWth of said cancer cells. 
The invention also provides a method comprising inhib 
iting cancer cell groWth by contacting said cancer cell in 
vitro or in vivo With an amount of a parthenolide derivative 
compound, effective to inhibit the groWth of said cancer cell. 
The invention also provides a parthenolide derivative 
compound for use in medical therapy (preferably for use in 
treating cancer, e.g. solid tumors), as Well as the use of a 
parthenolide derivative compound for the manufacture of a 
medicament useful for the treatment of cancer, e.g. solid 
tumors. 
The invention further provides methods of treating 
in?ammatory diseases and disorders, including, for 
example, rheumatoid arthritis, osteoarthritis, allergies (such 
as asthma), and other in?ammatory conditions, such as pain, 
sWelling, fever, psoriasis, in?ammatory boWel disease, gas 
trointestinal ulcers, cardiovascular conditions, including 
ischemic heart disease and atherosclerosis, partial brain 
damage caused by stroke, skin conditions (ecZema, sunburn, 
acne), leukotriene-mediated in?ammatory diseases of lungs, 
kidneys, gastrointestinal tract, skin, prostatitis, and parad 
ontosis. 
The invention further provides methods of treating 
immune response disorders, Whereby the immune response 
is inappropriate, excessive or lacking. Such disorders 
include allergic responses, transplant rejection, blood trans 
fusion reaction, and autoimmune disorders such as systemic 
lupus erythematosus and rheumatoid arthritis. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shoWs the effectiveness of parthenolide and deriva 
tives of the present invention in the clonogenic assay against 
prostate cancer cell line CWR22Rv1s. 
FIG. 2 shoWs the effectiveness of parthenolide and deriva 
tives of the present invention in the MTS-PMS assay against 
lung cancer cell lines A-549, H522, H-23 and H-460. 
FIG. 3 shoWs the effectiveness of parthenolide and deriva 
tives of the present invention in the MTS-PMS assay against 
breast cancer cell lines HBL-100, MD-231 and MD-436. 
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DETAILED DESCRIPTION OF THE 
INVENTION 
As used herein, “alkyl” refers to straight or branched 
chain alkyl groups having in the range of about 1 up to 20 
carbon atoms; “substituted alkyl” refers to alkyl groups 
further bearing one or more substituents such as hydroxy, 
alkoxy, mercapto, aryl, heterocyclic, halogen, tri?uorom 
ethyl, cyano, nitro, amino, carboxyl, carbamate, sulfonyl, 
sulfonamide and the like; “loWer alkyl” means 1 to 8 
carbons; 
“cycloalkyl” refers to cyclic ring-containing groups con 
taining in the range of about 3 up to 8 carbon atoms, and 
“substituted cycloalkyl” refers cycloalkyl groups further 
bearing one or more substituents as set forth above; 
“alkenyl” refers to straight or branched chain hydrocarbon 
groups having at least one carbon-carbon double bond, and 
having in the range of about 2 up to 20 carbon atoms, and 
“substituted alkenyl” refers to alkenyl groups further bearing 
one or more substituents as set forth above; 
“alkynyl” refers to straight or branched chain hydrocar 
bon groups having at least one carbon-carbon triple bond, 
and having in the range of about 2 up to 20 carbon atoms, 
and “substituted alkynyl” refers to alkynyl groups further 
bearing one or more substituents as set forth above; 
“aryl” refers to aromatic groups having in the range of 6 
up to 14 carbon atoms and “substituted aryl” refers to aryl 
groups further bearing one or more substituents as set forth 
above; 
“alkylaryl” refers to alkyl-substituted aryl groups and 
“substituted alkylaryl” refers to alkylaryl groups further 
bearing one or more substituents as set forth above; 
“arylalkyl” refers to aryl-substituted alkyl groups and 
“substituted arylalkyl” refers to arylalkyl groups further 
bearing one or more substituents as set forth above; 
“arylalkenyl” refers to aryl-substituted alkenyl groups and 
“substituted arylalkenyl” refers to arylalkenyl further bear 
ing one or more substituents as set forth above; 
“arylalkynyl” refers to aryl-substituted alkynyl groups 
and “substituted arylalkynyl” refers to arylalkynyl further 
bearing one or more substituents as set forth above; 
“aroyl” refers to aryl-carbonyl moiety such as benZoyl 
and “substituted aroyl” refers to aroyl groups further bearing 
one or more substituents as set forth above; 
“heterocyclic” refers to cyclic (i.e., ring-containing) 
groups containing one or more heteroatoms (e.g., N, O, S, or 
the like) as part of the ring structures, and having in the 
range of 3 up to 14 carbon atoms and “substituted hetero 
cyclic” refers to heterocyclic groups further bearing one or 
more substituents as set forth above; 
“acyl” refers to alkyl-carbonyl groups; and 
“halogen” refers to ?uoride, chloride, bromide, or iodide 
groups. 
The invention relates to the ability of the ot-methylene 
y-butyrolactone moiety in sesquiterpene lactones to be struc 
turally modi?ed by Michael addition With primary and/or 
secondary amines to form Water-soluble amino derivatives. 
Modi?cation of the parthenolide (1) molecule by this meth 
odology, affords amine adducts that can easily be obtained as 
different inorganic or organic salts to further increase Water 
solubility. Thus, a novel class of more Water-soluble par 
thenolide analogs is described. When compounds in this 
class Were evaluated for antileukemic activity, it Was found 
that these compounds Were either equipotent as, or more 
potent than the parent compound, parthenolide. More impor 
tantly, these novel analogs shoWed greater cytotoxicity 
toWards leukemia cells than toWards normal cells. Thus, the 
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4 
present invention provides a neW class of parthenolide 
derivatives With potent and selective anticancer activities. 
In accordance With the present invention, there are pro 
vided compounds having the general structure (2): 
NRIRZ 
Wherein: 
R1, R2 and R3 may be the same or different; 
R1 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, hydroxyalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub 
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, sub 
stituted arylalkyl, arylalkenyl, substituted arylalkenyl, ary 
lalkynyl, substituted arylalkynyl, heterocyclic, substituted 
heterocyclic, tri?uoromethyl, per?uoroalkyl, cyano, cya 
nomethyl, carboxyl, carbamate, sulfonyl, sulfonamide and 
aryloxyalkyl, or 0R1, Wherein, 0 is an oxygen; 
R2 is selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, hydroxyalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub 
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, sub 
stituted arylalkyl, arylalkenyl, substituted arylalkenyl, ary 
lalkynyl, substituted arylalkynyl, heterocyclic, substituted 
heterocyclic, tri?uoromethyl, per?uoroalkyl, cyano, cya 
nomethyl, carboxyl, carbamate, sulfonyl, sulfonamide and 
aryloxyalkyl; 
and its pharmaceutically acceptable salts formed With 
inorganic and/or organic acids, and including its quaternary 
ammonium salts formed With R4Y; Where Y is selected from 
halogen, tosylate, methanesulfonate, benZenesulfonate, trif 
luoromethanesulfonate and the like; and R4 is selected from 
alkyl, substituted alkyl, cycloalkyl, substituted alkyl, 
hydroxyalkyl, alkenyl, substituted alkenyl, alkynyl, substi 
tuted alkynyl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
cyanomethyl, alkyloxyalkyl and aryloxyalkyl. 
These acids include: hydro?uoric acid, hydrochloric acid, 
hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, 
phosphoric acid, carbonic acid, boric acid, selenious acid, 
hydrogen sul?de, phosphomolybdic acid, phosphorous acid, 
sulfurous acid, citric acid, maleic acid, D-malic acid, L-lac 
tic acid, D-lactic acid, DL-lactic acid, oxalic acid, methane 
sulfonic acid, valeric acid, oleic acid, lauric acid, paratolu 
enesulfonic acid, l-naphthalensulfonic acid, 
2-naphthalensulfonic acid, phthalic acid, tartaric acid, 
L-malic acid, DL-malic acid, malonic acid, succinic acid, 
fumaric acid, glycolic acid, thioglycolic acid, glycine, sar 
cocine, sulfonic acid, nicotinic acid, picolinic acid, isonico 
tinic acid, benZoic acid and substituted benZoic acid Which 
refers to the benZene ring further bearing one or more 
substituents as set forth beloW, and XCOOH Whereas X is 
selected from is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, hydroxyalkyl, alk 
enyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, 
substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, heterocyclic, substi 
US 7,312,242 B2 
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tuted heterocyclic, tri?uoromethyl, per?uoroalkyl, cyano, 
cyanomethyl, carboxyl, carbamate, sulfonyl, sulfonamide 
and aryloxyalkyl, or iOX and iSX. 
Presently preferred compounds of the invention are those 
wherein R1 is hydrogen or optionally substituted loWer 
alkyl; and R2 is optionally substituted loWer alkyl. 
According to one embodiment of the invention, R1 and R2 
are each iCH3. 
In another embodiment, R1 and R2 are each iCH2CH3. 
In a further embodiment, R1 is 4CH2CH3 and R2 is 
iCH3. 
In yet another embodiment of the invention, R1 is 
iCH2CH2CH3 and R2 is ‘CH3. 
According to another embodiment, R l is 4CH(CH3 )2 and 
R2 is ‘CH3. 
In an alternative embodiment of the present invention, R1 
and R2 can combine With N to form a ring system. Examples 
of such combination include 4CH2(CH2)nCH2i; Where n 
is selected from 0 to 5. These ring systems can also have one 
or more substituents selected from alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, hydroxyalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub 
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, sub 
stituted arylalkyl, arylalkenyl, substituted arylalkenyl, ary 
lalkynyl, substituted arylalkynyl, heterocyclic, substituted 
heterocyclic, tri?uoromethyl, per?uoroalkyl, cyano, cya 
nomethyl, carboxyl, carbamate, sulfonyl, sulfonamide, ary 
loxyalkyl and halogen as set forth above. 
This ring system can also be 4CH2(CH2)nCH2Z-; Where 
Z is O, S, Se, Si, P, 4COi, iSOi, iSOZi, iPOi; 
and 4CH2(CH2)nCH2i are the groups as set forth above. 
Alternatively, this ring system can be i(CH2)a-Z 
(CH2)bi; Where a and b are the same or different and are 
from 1 to 4; and Z is O, N, S, Se, Si, P, iCOi, iSOi, 
iSOZi or iPOi. This ring system can also be a uracil 
ring and its derivatives With one or more substituents. These 
ring systems can also have one or more substituents con 
nected to the carbon atom(s) and/or Z. The substituent is 
selected from alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, hydroxyalkyl, alkenyl, substituted alkenyl, alky 
nyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, 
substituted alkylaryl, arylalkyl, substituted arylalkyl, aryla 
lkenyl, substituted arylalkenyl, arylalkynyl, substituted ary 
lalkynyl, heterocyclic, substituted heterocyclic, tri?uorom 
ethyl, per?uoroalkyl, cyano, cyanomethyl, carboxyl, 
carbamate, sulfonyl, sulfonamide, aryloxyalkyl and halogen 
as set forth above. 
These ring systems can also be aromatic, such as pyrrole, 
imidaZole, purine, and pyraZole and substituted derivative of 
these heterocyclics listed above With one or more substitu 
ents selected from alkyl, substituted alkyl, cycloalkyl, sub 
stituted cycloalkyl, hydroxyalkyl, alkenyl, substituted alk 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, sub 
stituted arylalkynyl, heterocyclic, substituted heterocyclic, 
tri?uoromethyl, per?uoroalkyl, cyano, cyanomethyl, car 
boxyl, carboxylate, carboxaldehyde, carboxamide, carbam 
ate, hydroxy, alkoxy, isocyanate, isothiocyanate, nitro, 
nitroso, nitrate, sulfate, sulfonyl, sulfonamide, thiol, thio 
alkyl, aryloxyalkyl and halogen as set forth above. 
Any of the above ring systems comprising NRIR2 may 
optionally be fused With another ring to form an optionally 
substituted bicyclic or tricyclic ring system, each of the rings 
optionally comprising one or more heteroatoms. Preferred 
ring systems include aZiridin-l-yl, aZetidin-l-yl, pyrrolidin 
l-yl, piperidin-l-yl, homopiperidyn-l-yl and heptamethyl 
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6 
eneimin-l-yl, each being optionally substituted With one or 
more substituents as set forth above. 
Exemplary compounds of the present invention include: 
1 1 [3H, 1 3-Dimethylaminoparthenolide; 
l 1 [3H, 1 3-Diethylaminoparthenolide; 
l 1 [3H, 1 3-(tert-Butylamino)parthenolide; 
l 1 [3H, 1 3-(Pyrrolidin- l -yl)parthenolide; 
llBH, l 3-(Piperidin-l -yl)parthenolide; 
llBH, l 3-(Morpholin-l -yl)parthenolide; 
l 1 [3H, 1 3-(4-Methylpiperidin-l -yl)parthenolide; 
l 1 [3H, 1 3 -(4-MethylpiperaZin- l -yl)parthenolide; 
l 1 [3H, 1 3 -(Homopiperidin- l -yl)parthenolide; 
l 1 [3H, 1 3-(Heptamethyleneimin-l -yl)parthenolide; 
l 1 [3H, 1 3-(AZetidin-l -yl)parthenolide; and 
l 1 [3H, 1 3 -Diallylaminoparthenolide. 
Those of skill in the art recogniZe that invention com 
prises compounds that may contain one or more chiral 
centers on the iNRlRz group, and thus can exist as racemic 
mixtures as pure diastereomers, or as pure enantiomers. For 
many applications, it is preferred to carry out stereoselective 
synthesis and/ or to subject the reaction product to appropri 
ate puri?cation steps so as to produce substantially stere 
ochemically pure or optically pure materials. Suitable ste 
reoselective synthetic procedures for producing 
stereochemically pure or optically pure materials are Well 
knoWn in the art, as are procedures for resolving racemic 
mixtures into their optically pure enantiomers. 
The iNRlRz group may also be a primary amine or part 
of another anti-cancer drug moiety, constituting the forma 
tion of a “duplex aminoparthenolide analogue (Structure 3 
and Scheme II beloW) or the covalent union of parthenolide 
With basic nitrogen-containing synergistic anticancer drug 
molecules such as 5-?uorouracil, cytarabine, mytomycin C, 
Doxorubicin, Daunorubicin, (Scheme III, formula 4 beloW 
as a representative example), respectively. Thus, the present 
invention further provides compounds of the formula (3): 
Wherein R3 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, hydroxyalkyl, alk 
enyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, 
substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, heterocyclic, substi 
tuted heterocyclic, tri?uoromethyl, per?uoroalkyl, cyano, 
cyanomethyl, carboxyl, carbamate, sulfonyl, sulfonamide 
and aryloxyalkyl, or ORl, Wherein O is an oxygen; 
and its pharmaceutically acceptable salts formed With 
inorganic and/or organic acids, and its quaternary ammo 
nium salts formed With R4Y. Preferred R3 groups include H, 
alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, 
cycloalkynyl, alkylaryl, alkenylaryl and alkynylaryl. 
In accordance With another embodiment of the invention, 
the methods for the preparation of the amino analogs 
described in this invention are disclosed in Schemes I and II. 
US 7,312,242 B2 
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ene, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, pyri 
dine, carbon tetrachloride, diethyl ether, tert-butyl methyl 
sch?m? I ether and/or the mixture of tWo or more of the solvents listed 
above. The base is selected from a loW trialkylamine, such 
5 as trimethylamine, triethylamine, tripropylamine, and tribu 
tylamine, and pyridine, 2-, 3-, and 4-picolines, 2-, 3-, and 
4-dimethylaminopyridines. The temperature is selected from 
—200 C. to 130° C. The reaction time required to effect the 
desired coupling reaction can vary Widely, typically falling 
10 in the range of 30 min to 24 hours. Puri?cation can be 
achieved by a variety of techniques, such as, liquid chro 
matography through neutral or basic silica gel, bonded silica 
gel phases such as octadecylsilica, octylsilica and the like, 
----|||| cellulose or alumina With the solvent such as, for example, 
15 the mixture of chloroform and methanol or ethanol, the 
4, 
solvent, base 
temp erature 
NRIRZ mixture of methylene chloride and methanol or ethanol, the 
0 mixture of hexane and acetone or acetonitrile or methanol or 
2 ethanol or isopropanol, the mixture of diethyl ether and 
Scheme 11 acetone or acetonitrile or methanol or ethanol or isopro 
20 panol; and recrystallization using normal organic solvent or 
solvent mixture, such as methanol, ethanol, propanol, iso 
R3NH2 propanol, tert-butanol, acetonitrile, diethyl ether, chloro 
Solvent bas? form, methylene chloride and the mixture of tWo or more 
wmpefamre solvents listed above. The purity of the invention com 
0 25 pounds prepared is assessed by mass spectrometry, nuclear 
magnet resonance spectrometry and elemental combustion 
analys1s. 
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DUPLEX ANALOG 
S-Fluorouracil-Parthenolide Codrug 
In the above scheme, R1 and R2 are de?ned as previously; 40 
and the solvent is selected from a loW alkyl alcohol, such as Furthermore, in accordance With still another embodiment 
methanol, ethanol, propanol, isopropanol, n-butanol, tert- of the present invention, the methods for the preparation of 
butanol, and chloroform, methylene chloride, benzene, tolu- the invention salts are disclosed in Schemes IV and V. 
Schemelll 
Acid HX 
...-|||| W ---||||| 
NR lNR2 temperature NR1 R2 
'HX 
O O 
2 5 
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In these schemes, HX is selected from hydrochloride, 
hydrobromide, hydroiodide, perchlorate, sulfate, hemisul 
fate mesylate, toluenesulfonate, benZenesulfonate, succi 
nate, hemisuccinate, fumarate, acetate, hemifumarate, male 
ate, maleate, citrate, oxalate, malonate, propionate and 
benZoate; Y6) is selected from halide (?uoride, chloride, 
bromide, iodide), methylsulfonate, toluenesulfonate, benZe 
nesulfonate and sulfate; and the solvent is selected from a 
loW alkyl alcohol, such as diethyl ether, methanol, ethanol, 
propanol, isopropanol, n-butanol, tert-butanol, and chloro 
form, methylene chloride, benzene, toluene, tetrahydrofu 
ran, dioxane, l,2-dimethoxyethane, pyridine, carbon tetra 
chloride, tert-butyl methyl ether, acetone and/ or the mixture 
of tWo or more of the solvents listed above. The temperature 
is selected from —200 C. to 50° C. Puri?cation can be 
achieved by recrystallization using normal organic solvent 
or solvent mixture, such as methanol, ethanol, acetone, 
propanol, isopropanol, t-butanol, acetonitrile, diethyl ether, 
chloroform, methylene chloride and the mixture of tWo or 
more solvents listed above. 
3 
DUPLEX ANALOG 
20 
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Also part of the invention are analogues of the same type 
as above for the folloWing structurally related parthenolide 
like constituents: costunolide, dehyrocostuslactone, alanto 
lactone, isoalantolactone, amino-3-oxo-isoalantolactone, 
helenalin, ll,l3-dihydrohelenalin, aminocyanaropicrin, 
aminodesacylcyanaropicrin, (+)-aminoreyonosin, ami 
nosantamarin, aminosoulangianolide, and aminoisotelekin 
(see Scheme VI). 
Schemell 
O 
Dehydrocostuslactone Alantolactone 
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-continued 
HOQH o 
Helenalin lsoalantolactone 
Costunolide ll, 13 —Dihydrohelenalin 
O 
OH 
-- mil O 
...,,,U 
NR 1R2 
O 
Aminocynaropicrins 
NRIRZ 
o 
Aminodesacylcynaropicrins 
OH 
NRIRZ 
O 
(+)—Aminoreynosins 
OH 
NRIRZ 
O 
Amino santamarins 
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-continued 
OH 
NRIRZ 
O 
Aminosoulangianolides 
H 
Amino-3-oXo-isoalantolactones 
HO 
Aminoisotelekins 
The compounds described herein are useful for treating 
cancer. Cancers treatable by the present therapy include the 
solid and hematological tumors, such as prostate cancer, 
ovarian cancer, breast cancer, brain cancer and hepatic 
cancer, comprising administering to a mammal a?licted With 
said cancer an amount of parthenolide derivative effective to 
inhibit the viability of cancer cells of said mammal. The 
parthenolide derivative may be administered as primary 
therapy, or as adjunct therapy, either folloWing local inter 
vention (surgery, radiation, local chemotherapy) or in con 
junction With at least one other chemotherapeutic agent. 
discussed hereinabove, as Well as the solid tumors disclosed 
in Us. Pat. No. 5,514,555. Hematological cancers, such as 
the leukemias are disclosed in the Mayo Clinic Family 
Health Book, D. E. Larson, ed., William MorroW, NY. 
(1990) and include CLL, ALL, CML and the like. 
Within another aspect of the present invention, methods 
are provided for inhibiting angiogenesis in patients With 
non-tumorigenic, angiogenesis-dependent diseases, com 
prising administering a therapeutically effective amount of a 
composition comprising parthenolide derivative to a patient 
With a non-tumorigenic angiogenesis-dependent disease, 
such that the formation of neW blood vessels is inhibited. 
Within other aspects, methods are provided for inhibit 
reactive proliferation of endothelial cells or capillary for 
mation in non-tumorigenic, angiogenesis-dependent dis 
eases, such that the blood vessel is effectively occluded. 
Within one embodiment, the anti-angiogenic composition 
comprising parthenolide derivative is delivered to a blood 
vessel Which is actively proliferating and nourishing a 
tumor. 
In addition to tumors, numerous other non-tumorigenic 
angiogenesis-dependent diseases, Which are characteriZed 
by the abnormal groWth of blood vessels, may also be 
treated With the anti-angiogenic parthenolide derivative 
compositions, or anti-angiogenic factors of the present 
invention. Anti-angiogenic parthenolide derivative compo 
sitions of the present invention can block the stimulatory 
US 7,312,242 B2 
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effects of angiogenesis promoters, reducing endothelial cell 
division, decreasing endothelial cell migration, and impair 
ing the activity of the proteolytic enzymes secreted by the 
endothelium. Representative examples of such non-tumori 
genic angiogenesis-dependent diseases include corneal 
neovasculariZation, hypertrophic scars and keloids, prolif 
erative diabetic retinopathy, arteriovenous malformations, 
atherosclerotic plaques, delayed Wound healing, hemophilic 
joints, nonunion fractures, Osler-Weber syndrome, psoriasis, 
pyogenic granuloma, scleroderma, trachoma, menorrhagia, 
retrolental ?broplasia and vascular adhesions. The pathol 
ogy and treatment of these conditions is disclosed in detail 
in published PCT application PCT/CA94/00373 (WO 
95/03036), at pages 26436. Topical or directed local admin 
istration of the present compositions is often the preferred 
mode of administration of therapeutically effective amounts 
of parthenolide derivative, i.e., in depot or other controlled 
release forms. 
Anti-angiogenic compositions of the present invention 
may also be utiliZed in a variety of other manners. For 
example, they may be incorporated into surgical sutures in 
order to prevent stitch granulomas, implanted in the uterus 
(in the same manner as an IUD) for the treatment of 
menorrhagia or as a form of female birth control, adminis 
tered as either a peritoneal lavage ?uid or for peritoneal 
implantation in the treatment of endometriosis, attached to a 
monoclonal antibody directed against activated endothelial 
cells as a form of systemic chemotherapy, or utiliZed in 
diagnostic imaging When attached to a radioactively labelled 
monoclonal antibody Which recogniZes active endothelial 
cells. 
The magnitude of a prophylactic or therapeutic dose of 
parthenolide derivative, an analog thereof or a combination 
thereof, in the acute or chronic management of cancer, i.e., 
prostate or breast cancer, Will vary With the stage of the 
cancer, such as the solid tumor to be treated, the chemo 
therapeutic agent(s) or other anti-cancer therapy used, and 
the route of administration. The dose, and perhaps the dose 
frequency, Will also vary according to the age, body Weight, 
and response of the individual patient. In general, the total 
daily dose range for parthenolide derivative and its analogs, 
for the conditions described herein, is from about 0.5 mg to 
about 2500 mg, in single or divided doses. Preferably, a 
daily dose range should be about 1 mg to about 100 mg, in 
single or divided doses, most preferably about 5450 mg per 
day. In managing the patient, the therapy should be initiated 
at a loWer dose and increased depending on the patient’s 
global response. It is further recommended that infants, 
children, patients over 65 years, and those With impaired 
renal or hepatic function initially receive loWer doses, and 
that they be titrated based on global response and blood 
level. It may be necessary to use dosages outside these 
ranges in some cases. Further, it is noted that the clinician or 
treating physician Will knoW hoW and When to interrupt, 
adjust or terminate therapy in conjunction With individual 
patient response. The terms “an effective amount” or “an 
effective sensitiZing amount” are encompassed by the 
above-described dosage amounts and dose frequency sched 
ule. 
Any suitable route of administration may be employed for 
providing the patient With an effective dosage of partheno 
lide derivative (e.g., oral, sublingual, rectal, intravenous, 
epidural, intrethecal, subcutaneous, transcutaneous, intra 
muscular, intraperitoneal, intracutaneous, inhalation, trans 
dermal, nasal spray, nasal gel or drop, and the like). While 
it is possible that, for use in therapy, parthenolide derivative 
or its analogs may be administered as the pure chemicals, as 
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by inhalation of a ?ne poWder via an insul?ator, it is 
preferable to present the active ingredient as a pharmaceu 
tical formulation. The invention thus further provides a 
pharmaceutical formulation comprising parthenolide deriva 
tive or an analog thereof, together With one or more phar 
maceutically acceptable carriers therefor and, optionally, 
other therapeutic and/or prophylactic ingredients. The car 
rier(s) must be ‘acceptable’ in the sense of being compatible 
With the other ingredients of the formulation and not del 
eterious to the recipient thereof, such as a human patient or 
domestic animal. 
Pharmaceutical formulations include those suitable for 
oral or parenteral (including intramuscular, subcutaneous 
and intravenous) administration. Forms suitable for 
parenteral administration also include forms suitable for 
administration by inhalation or insuf?ation or for nasal, or 
topical (including buccal, rectal, vaginal and sublingual) 
administration. The formulations may, Where appropriate, be 
conveniently presented in discrete unit dosage forms and 
may be prepared by any of the methods Well knoWn in the 
art of pharmacy. Such methods include the step of bringing 
into association the active compound With liquid carriers, 
solid matrices, semi-solid carriers, ?nely divided solid car 
riers or combinations thereof, and then, if necessary, shaping 
the product into the desired delivery system. 
Pharmaceutical formulations suitable for oral administra 
tion may be presented as discrete unit dosage forms such as 
hard or soft gelatin capsules, cachets or tablets each con 
taining a predetermined amount of the active ingredient; as 
a poWder or as granules; as a solution, a suspension or as an 
emulsion; or in a cheWable base such as a synthetic resin or 
chicle for ingestion of the agent from a chewing gum. The 
active ingredient may also be presented as a bolus, electuary 
or paste. Tablets and capsules for oral administration may 
contain conventional excipients such as binding agents, 
?llers, lubricants, disintegrants, or Wetting agents. The tab 
lets may be coated according to methods Well knoWn in the 
art, i.e., With enteric coatings. 
Oral liquid preparations may be in the form of, for 
example, aqueous or oily suspensions, solutions, emulsions, 
syrups or elixirs, or may be presented as a dry product for 
constitution With Water or other suitable vehicle before use. 
Such liquid preparations may contain conventional additives 
such as suspending agents, emulsifying agents, non-aqueous 
vehicles (Which may include edible oils), or preservatives. 
The compounds according to the invention may also be 
formulated for parenteral administration (e.g., by injection, 
for example, bolus injection or continuous infusion) and 
may be presented in unit dose form in ampules, pre-?lled 
syringes, small volume infusion containers or in multi-dose 
containers With an added preservative. The compositions 
may take such forms as suspensions, solutions, or emulsions 
in oily or aqueous vehicles, and may contain formulatory 
agents such as suspending, stabiliZing and/or dispersing 
agents. Alternatively, the active ingredient may be in poWder 
form, obtained by aseptic isolation of sterile solid or by 
lyophiliZation from solution, for constitution With a suitable 
vehicle, e.g., sterile, pyrogen-free Water, before use. 
For topical administration to the epidermis, the com 
pounds may be formulated as ointments, creams or lotions, 
or as the active ingredient of a transdermal patch. Suitable 
transdermal delivery systems are disclosed, for example, in 
A. Fisher et al. (US. Pat. No. 4,788,603), or R. BaWa et al. 
(US. Pat. Nos. 4,931,279; 4,668,506 and 4,713,224). Oint 
ments and creams may, for example, be formulated With an 
aqueous or oily base With the addition of suitable thickening 
and/or gelling agents. Lotions may be formulated With an 
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aqueous or oily base and Will in general also contain one or 
more emulsifying agents, stabilizing agents, dispersing 
agents, suspending agents, thickening agents, or coloring 
agents. 
Formulations suitable for topical administration in the 
mouth include unit dosage forms such as lozenges compris 
ing active ingredient in a ?avored base, usually sucrose and 
acacia or tragacanth; pastilles comprising the active ingre 
dient in an inert base such as gelatin and glycerin or sucrose 
and acacia; mucoadherent gels, and mouthWashes compris 
ing the active ingredient in a suitable liquid carrier. 
When desired, the above-described formulations can be 
adapted to give sustained release of the active ingredient 
employed, e.g., by combination With certain hydrophilic 
polymer matrices, e.g., comprising natural gels, synthetic 
polymer gels or mixtures thereof. The polymer matrix can be 
coated onto, or used to form, a medical prosthesis, such as 
a stent, valve, shunt, graft, or the like. 
Pharmaceutical formulations suitable for rectal adminis 
tration Wherein the carrier is a solid are most preferably 
presented as unit dose suppositories. Suitable carriers 
include cocoa butter and other materials commonly used in 
the art, and the suppositories may be conveniently formed by 
admixture of the active compound With the softened or 
melted carrier(s) folloWed by chilling and shaping in molds. 
Formulations suitable for vaginal administration may be 
presented as pessaries, tampons, creams, gels, pastes, foams 
or sprays containing, in addition to the active ingredient, 
such carriers as are knoWn in the art to be appropriate. 
For administration by inhalation, the compounds accord 
ing to the invention are conveniently delivered from an 
insuf?ator, nebulizer or a pressurized pack or other conve 
nient means of delivering an aerosol spray. Pressurized 
packs may comprise a suitable propellant such as dichlo 
rodi?uoromethane, trichloro?uoromethane, dichlorotet 
ra?uoroethane, carbon dioxide or other suitable gas. In the 
case of a pressurized aerosol, the dosage unit may be 
determined by providing a valve to deliver a metered 
amount. 
Alternatively, for administration by inhalation or insuf 
?ation, the compounds according to the invention may take 
the form of a dry poWder composition, for example, a 
poWder mix of the compound and a suitable poWder base 
such as lactose or starch. The poWder composition may be 
presented in unit dosage form in, for example, capsules or 
cartridges or, e.g., gelatin or blister packs from Which the 
poWder may be administered With the aid of an inhalator or 
insuf?ator. 
For intra-nasal administration, the compounds of the 
invention may be administered via a liquid spray, such as via 
a plastic bottle atomizer. Typical of these are the Mistom 
eter.RTM. (Wintrop) and the Medihaler.RTM. (Riker). 
For topical administration to the eye, the compounds can 
be administered as drops, gels (US. Pat. No. 4,255,415), 
gums (see US. Pat. No. 4,136,177) or via a prolonged 
release ocular insert. 
The invention Will noW be described in greater detail by 
reference to the folloWing non-limiting examples. 
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EXAMPLES 
Example 1 
General Synthetic Procedure for the Preparation of 
11[3H,13-Substituted Aminoparthenolides 
A mixture of parthenolide (100 mg, 0.4 mmol), the 
appropriate primary amine or secondary amine (2 mmol), 
and triethylamine (1 to 2 ml) in 30 ml of anhydrous ethanol 
Was stirred at a speci?c temperature ranging from ambient 
temperature to the temperature of the re?uxing solvent 
utilized, or Was left to stand in the refrigerator (—200 C. to 
40 C.) overnight for 24 hours. Ethanol, triethylamine and/or 
the appropriate volatile amine Were then evaporated under 
vacuum in a rotavapor. The resulting residue Was subjected 
to silica gel column chromatographic puri?cation using 
chloroform-methanol or methylene chloride-methanol 
mixed solvent as the mobile phase. NMR (Varian, 300 MHz 
and 400 MHz) and GC/MS (Agilent, 6890GC and 
5973MSD) analysis methodologies Were utilized to assure 
the identity and purity of the synthetic compounds. 
Example 2 
1 1 [3H, 13 -Dimethylaminoparthenolide 
Parthenolide (100 mg, 0.4 mmol), dimethylamine(2M in 
methanol, 1 ml), triethylamine (2 ml), ethanol (30 ml) Were 
re?uxed overnight. After column puri?cation, 109 mg of 
pale yelloW 11[3H,13-dimethylaminoparthenolide Was 
obtained (Yield: 93%). 
Example 3 
1 1[3H,13 -Diethylaminoparthenolide 
Parthenolide (100 mg, 0.4 mmol), diethylamine (200 mg, 
2.7 mmol), triethylamine (2 ml), ethanol (30 ml) Were 
re?uxed overnight. After column puri?cation, 114 mg of 
yelloW 11H,13-Diethylaminoparthenolide Was obtained 
(Yield: 88%). 
Example 4 
Preparation of Salts of Aminoparthenolide 
Derivatives 
The aminoparthenolide derivative Was dissolved in anhy 
drous ether and to this solution Was added the corresponding 
acid in ether or ethanol. The mixture Was kept in the 
refrigerator (40 C.) overnight. The crystals formed Was 
?ltered and dried under vacuum, or submitted to further 
recrystallization, if needed. 
Example 5 
Preparation of 11 [3H,13-(piperidin-1-yl)parthenolide 
hydrochloride 
11[3H,13-(piperidin-1-yl)parthenolide (5 mg) Was dis 
solved in 2 ml of dry ether. Hydrochloride in ether (1M, 
0.015 ml) Was added to the ether solution until the solution 
became cloudy; then more ether Was added and the mixture 
Was heated to obtain a clear solution. The mixture Was left 
in refrigerator (40 C.) for more than 24 hours. The White 
crystals that formed Were ?ltered through ?lter paper, and 
dried under vacuum overnight (Yield: 18%). 
US 7,312,242 B2 
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Example 6 
Preparation of 11 [3H, 13-dimethylaminoparthenolide 
maleate 
To 11[3H,13-dimethylaminoparthenolide (30 mg, 0.1 
mmol) in anhydrous ethanol (5 ml) Was added maleic acid 
(12 mg, 0.1 mmol) in 3 ml of anhydrous ethanol. The 
solution Was shaken Well and ?ltered through a regular ?lter 
paper. The clear solution Was left in the refrigerator for a 
Week. The White crystals formed Were obtained by ?ltration, 
dried in a desiccator under vacuum With anhydrous CaCl2 
(Yield: 55%). 
Example 7 
Preparation of 11[3H, 
13-Dimethylaminoparthenolide methiodide 
To 11[3H,13-dimethylaminoparthenolide (30 mg, 0.1 
mmol) in anhydrous methanol (5 ml) Was added 
iodomethane (90 mg, 0.6 mmol) in methanol (1 ml). The 
clear solution Was shaken and stored at room temperature. 
After three days, the methanol Was evaporated, the pale 
yelloW residue Was dried in a desiccator under vacuum, over 
anhydrous CaCl2. Recrystallization from acetone-ether 
afforded pale yelloW crystals (Yield: 86%). 
Example 8 
1 1 [3H,13 -(4-Methylpiperidin-1-yl)parthenolide methio 
dide: To 11[3H,13-(4-methylpiperidin-1-yl)parthenolide (35 
mg, 0.1 mmol) in anhydrous methanol (5 ml) Was added 
iodomethane (90 mg, 0.6 mmol) in methanol (1 ml). The 
clear solution Was shaken and stored at room temperature. 
20 
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After three days, the methanol Was evaporated, the pale 
yelloW residue Was dried in a desiccator under vacuum, over 
anhydrous CaCl2. Recrystallization from acetone-ether 
afforded pale yelloW crystals (Yield: 79%). 
Example 9 
Assay for Antileukemic Activity 
For apoptosis analysis, one million primary acute myel 
ogenous leukemia cells Were Washed With cold PBS and 
resuspended in 200 microliters of Annexin binding bulfer 
(10 mM HEPES/NaOH pH 7.4; 140 mM NaCl; 2.5 mM 
CaCl2). Annexin V-FITC (Pharmingen) and 0.25 mg/ml 
7-AAD (7-aminoactinomycin D, Molecular Probes, CA) 
Were added and the tubes Were incubated at room tempera 
ture in the dark for 15 minutes. Cells Were then diluted With 
200 microliters of Annexin binding bulfer and analyzed 
immediately by How cytometry. Viable cells Were identi?ed 
as failing to label With Annexin V or 7-AAD. Cells begin 
ning to die label With Annexin V, and as membrane integrity 
is lost, Will also label With 7-AAD. For each parthenolide 
derivative, the percentage of viable cells Was determined 
after 24 hours of culture at a 10 micromolar concentration. 
Data are normalized to untreated control specimens. The 
data are in Table 1 for aminoparthenolide derivatives and 
Table 2 for the salts of some aminoparthenolides. 
Healthy human bone marroW cells Were used in the above 
assay to test the cytotoxicity of parthenolide. Eighty-?ve 
percent of the normal cells survived 10 11M of parthenolide. 
All the aminoparthenolides evaluated afforded similar 
results to parthenolide, i.e. the survival rate of healthy 
human bone marroW cells Was over 85% at a concentration 
of 10 11M. 
TABLE 1 
Compound 
Aminoparthenolides and their antileukemic activi? 
Yield Antileukemic 
(%) activity 
Reaction 
Conditions 
Reactants and 
S o lvent 
Dimethylalninoparthenolide 
Diethylalninoparthenolide 
Butylamino)pa1thenolide 
yl)pa1thenolide 
yl)pa1thenolide 
Parthenolide 
(100 mg), 
dimethylalnine (2 M 
in methanol, 1 ml), 
triethylalnine(2 ml), 
ethanol (30 ml) 
Parthenolide 
(100 mg), 
diethylalnine 
(200 mg, 2.7 mmol), 
triethylalnine (2 ml), 
ethanol (30 ml) 
Parthenolide 
(20 mg), tert 
butylalnine (0.2 ml), 
triethylalnine 
(0.4 ml), ethanol 
(5 m1) 
Parthenolide 
(30 mg), pyrrolidine 
(0.2 m1), 
triethylalnine 
(0.2 ml), ethanol (5 ml) 
Parthenolide 
(250 mg), piperidine 
(1 ml), triethylalnine 
(5 ml), ethanol 
(100 m1) 
Re?uxin g 
overnight 
93 5 11M, 31% 
10 11M, 90% 
20 11M, 95% 
overnight 
10 11M, 60% 
10 hours 
10 11M, 20% 
12 hours 
5 11M, 23% 
10 11M, 85% 
20 11M, 95% 
overnight 
2.5 11M, 71% 
5 11M, 91% 
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Aminoparthenolides and their antileukemic activity 
Reactants and Reaction Yield Antileukemic 
Compound Solvent Conditions (%) activity 
11[3H,13—(Morpholin—1— Parthenolide Refluxing 91 5 M, 5% 
yl)parthenolide (100 mg), overnight 20 uM, 20% 
morpholine (0.5 ml), 
triethylamine (2 ml), 
ethanol (30 ml) 
11[5H,13-(4— Parthenolide Refluxing 89 10 uM, 83% 
Methylpiperidin-l- (100 mg), 4- overnight 
yl)parthenolide methylpiperidine 
(0.5 ml), 
triethylamine (2 ml), 
ethanol (30 ml) 
11[5H,13-(4— Parthenolide Refluxing 74 10 uM, 7% 
Methylpiperazin-l- (30 mg), 4- overnight 
yl)parthenolide methylpiperaZine 
(0.2 ml), 
triethylamine (1 ml), 
ethanol (20 ml) 
11[3H,13—(Homopiperidin— Parthenolide Refluxing 82 10 uM, 40% 
1—yl)parthenolide (100 mg), overnight 
homopiperidine 
(500 mg), 
triethylamine (2 ml), 
ethanol (30 ml) 
11[3H,13— Parthenolide Refluxing 74 10 uM, 10% 
(Heptamethyleneimin-l- (100 mg), overnight 
yl)parthenolide heptamethyleneimin 
(500 mg), 
triethylamine (2 ml), 
ethanol (30 ml) 
11[5H,13—(AZetidin-1— Parthenolide Stirred at 93 
yl)parthenolide (100 mg), aZetidine room 
(100 mg), temperature 
triethylamine (2 ml), 2 days 
ethanol (20 ml) 
11[3H,13— Parthenolide Refluxing 57 
Diallylaminoparthenolide (100 mg), overnight 
diallylamine 
(200 mg), 
triethylamine (2 ml), 
ethanol (30 ml) 
TABLE 2 
Aminoparthenolide salts and their antileukemic activity 
Reaction Yield Antileukemic 
Compound Reactants and Solvent Conditions (%) activity 
11[3H,13— 11[5H,13— Refrigerator, 72 
Dimethylaminoparthenolide Dimethylaminoparthenolide 24 hours 
hydrochloride (10 mg), HCl in ether (1 M, 
0.03 ml) 
11[5H,13—(Pyrrolidin—1— 11[5H,13—(Pyrrolidin—1— Refrigerator, 10 10 uM, 85% 
yl)parthenolide yl)parthenolide (5 mg), HCl 24 hours 
hydrochloride in ether (1 M, 0.015 ml) 
11[3H,1 3-(Piperidin-1 — 11[3H, 13-(Piperidin- 1- Refrigerator, 18 10 uM, 88% 
yl)parthenolide yl)parthenolide (5 mg), HCl 24 hours 
hydrochloride in ether (1 M, 0.015 ml) 
11[5H,13-(4— 11[3H,13-(4— Refrigerator, 38.3 10 uM, 62% 
Methylpiperidin-l- Methylpiperidin-l- 4 days 
yl)parthenolide yl)parthenolide (50 mg), 
hydrochloride HCl in ether (1 M, 0.15 ml) 
11[5H,13- 11[5H,13- Room 55 
Dimethylaminoparthenolide Dimethylaminoparthenolide temperature 
maleate (30 mg), maleic acid for 1 Week 
(12 mg), ethanol (8 ml) 
11[5H,13- 11[5H,13- Room 86 
Dimethylaminoparthenolide Dimethylaminoparthenolide temperature 
methiodide (30 mg), added iodomethane for 3 days 
(90 mg), methanol (6 ml) 
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Aminoparthenolide salts and their antileukemic activity 
Reaction Yield Antileukemic 
Compound Reactants and Solvent Conditions (%) activity 
11[5H,13-(4- 11|3H,13-(4- Room 79 
Methylpiperidin- 1 — Methylpip eridin- 1 — temperature 
yl)parthenolide methiodide yl)parthenolide (70 mg), for 3 days 
iodomethane (200 mg), 
methanol (12 ml) 
Example 10 
Analysis of Parthenolide and 
Dimethylaminoparthenolide (DMAPT) Using 
Human-Mouse Xenografts 
To assess the effect of parthenolide on primary human 
stem cell populations, experiments were conducted using 
transplantation into immune de?cient NOD/SCID mice. 
Successful engraftment of NOD/SCID bone marrow at 648 
weeks post-transplant has been shown to be a measure of 
stem cell content for human hematopoietic cell populations 
(Lapidot et al., JMol Med. 1997; 75:6644673; Dick, Curr 
Opin Hematol. 1996; 3:4054109). For each experiment, 
cryopreserved mononuclear cell specimens from normal or 
AML donors were thawed, and treated in vitro with 7.5 
micromolar parthenolide for 12418 hours. Following cul 
ture, 5410 million cells/animal were injected intravenously 
into sublethally irradiated (300 Rad) NOD/SCID mice. After 
648 weeks, animals were sacri?ced and bone marrow was 
analyzed for the presence of human cells using ?ow cytom 
etry as previously described (Guzman et al., Proc Natl Acad 
Sci USA 2002; 99: 1622(L162253). Human speci?c antibod 
ies for CD45 were used to assess the level of total engraft 
ment. 
In three independent experiments, the level of engraft 
ment for parthenolide-treated AML cells was dramatically 
reduced, which indicates a direct e?fect on the AML stem 
cell compartment. In contrast, no reduction in engraftment 
was detected for parthenolide-treated normal specimens, 
thus showing the parthenolide does not target normal 
hematopoietic stem cells. Similarly, treatment of AML cells 
with 7.5 micromolar DMAPT also yielded a strong reduc 
tion in NOD/SCID engraftment while treatment of normal 
cells showed no signi?cant elTects. 
Example 11 
MTS-PMS Assay 
Details of MTS-PMS assayi96-well U-bottomed plate 
(Becton Dickinson Labware, Franklin Lakes, N.J.) at a 
concentration of 5,000 cells per 50 microliters (mL) of 
media and incubated in 5% CO2 at 370 C. for 24 hours. 
Varying compound concentrations in 50 mL of media were 
added to the media 24 hours later. Colorimetric readings 
were obtained using the MTS/PMS system and an ELISA 
plate reader, after 48 hours of exposure to DMAPT. The 
readings obtained for each concentration tested were from 
an average of eight wells. Each experiment was expressed as 
a percentage of the solvent control and completed at least 
three times with consistent results. The results presented are 
an average of three experiments. The hormone refractory 
prostate cancer cell line CWR22Rv1 was treated with 
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increasing concentrations of parthenolide and derivatives for 
three hours (FIG. 1). Cellular proliferation was reduced by 
50% by 5 pm in the MTS-PMS assay. 
Example 12 
Clonogenic Assay 
Initially, 100 cells growing in log phase are plated per 3 
ml of media in each well of six well plate. After 24 hrs of 
plating of the cells, DMAPT was added at varying concen 
trations. At 24 and 96 hours after addition of drug, the media 
is changed. Hence, the cells are only exposed to the drug for 
24 hrs only. When cell colonies appear at Day 15 they are 
stained by Sure Stain Dye for 15 and counted. 
Example 13 
cDNA Array Analysis 
Total cellular RNA was extracted from the human mono 
cyte cell line THP-l under three conditions 2 hours after 
Time 0: 
1) Control was added at Time 0 
2) Lipopolysacchride (10 nM) was added at Time plus one 
(1) hour 
3) At Time 0, 10 micromoles of DMAPT was added and 
then at Time+1 LPS (10 nM) was added. 
RNA was extracted using RNeasy Min Kit (Qiagen, USA) 
according to the manufacturer’s instructions. The Human 
Drug Targets for In?ammation and Immunomodulation Q 
series GE array kit (HS-048-12) was obtained from Super 
Array Bioscience Corporation (Frederick, Md.). The kit 
determines expression of 96 genes that are associated with 
in?ammation. RNA from respective samples was used as a 
template to generate biotin labeled cDNA probes using 
GEArray Ampolabelling RT kit (SuperArray, Bioscience 
Corp., USA). The cDNA probes corresponding to the mRNA 
population were then denatured and hybridization was car 
ried out in GEHyb solution to nylon membranes spotted 
with gene speci?c fragments. Membranes were then washed 
in 2><SSC, 1% SDS twice for 15 minutes each, followed by 
0.1 SSC, 0.5% SDS twice for 15 minutes each. Chemilu 
minescence was used to visualize the expression levels of 
each transcript and the results were quanti?ed with the 
GEArray Analyzer. The change in a given gene transcript 
was estimated by normalizing the signal intensities with the 
signal derived from PPIA and with minimum background 
subtraction. 
As can be seen in Table 3, transcription of 25 genes was 
increased after pre-treatment with LPS. More importantly 
pretreatment with DMAPT prevented or blunted the increase 
in gene transcription induced by LPS. For example, the 
transcription of tumor necrosis factor (TNF), released in 
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septic shock, is increased by 3 fold (298%) When treated 
With LPS. Pretreatment With DMAPT however prevents 
transcription of LPS and in fact decreases its production to 
2% of control. Similarly, transcription of cyclo-oxygenase 
2, the target of classical non-steroidal anti-in?ammatory 
agents, Was increased 1.5 fold (150%). In the presence of 
DMAPT, the gene expression not only prevented the 
increase by LPS but decreased it to 30% (0.7) of solvent 
control. 
TABLE 3 
cDNA Array Analysis 
LPS DMAPT Pre 
Treatment treatment for 2 
for 1 hour: hours then 1 hour 
% Change Treatment of LPS 
Gene of Gene % Change of Genes 
CD28 antigen (Tp44) 23 0.814 
CD3G antigen, gamma polypeptide 14 0.6 
(TiT3 complex) 
Colony stimulating factor 2 26 0.926 
(granulocyte-macrophage) 
Intercellular Adhesion Molecule 1 257 58 
Interleukin 13 93 0.64 
Interleukin 1 receptor, type I 10 0.33 
Interleukin 1 receptor, type II 326 0.74 
Nitric oxide synthase 2A (inducible) 226 48 
Phosphodiesterase 4A, cAMP-speci?c 14 0.46 
Phosphodiesterase 4B, cAMP-speci?c 220 0.59 
Phospholipase A2, group IB (pancreas) 114 0.57 
Phospholipase A2, group IVC 350 0.89 
Phospholipase A2, group VII 129 0.05 
Phospholipase C, gamma 1 342 0.24 
Peroxisome proliferative activated 49 0.48 
receptor, gamma 
Platelet-activating factor receptor 32 0.002 
Prostaglandin D2 receptor (DP) 35 0.17 
Prostaglandin F receptor (PP) 879 1.46 
Cyclooxygenase 1 176 0.731 
Cyclooxygenase 2 152 0.7 
Thromboxane A synthase 1 283 0.07 
Tumor necrosis factor 298 0.02 
(TNF superfamily, member 2) 
Tumor necrosis factor (ligand), 217 0.89 
superfamily member 13b 
Tumor necrosis factor (ligand) 692 23 
superfamily, member 5 
Vascular cell adhesion molecule 1 154 0.02 
Example 14 
Parthenolide and Derivative Assay Activity 
Presented herein is data demonstrating that: compounds 
of the present invention reduce the viability of and increases 
sensitivity to chemotherapy of lung cancer, prostate, and 
breast cancer cell lines as Well as decrease in?ammation by 
decreasing cytokines as evidenced by decreased genes in 
human monocytes. 
The hormone refractory prostate cancer cell line 
CWR22Rv1 Was treated With increasing concentrations of 
parthenolide derivatives DMAPT, PIPT and 4MEPT for 
three hours. Cellular proliferation Was reduced by up to 80% 
at 2 um in the clonogenic assay and by 50% by 5 u/m in the 
MTS-PMS assay (FIG. 1). 
Cellular proliferation Was measured in the MTS-PMS 
assay of the four lung cancer cell lines to parthenolide and 
derivatives PipPT ((11[3H, 13-(piperidin-1-yl)parthenolide), 
4MePipPT (11 [3H, 13-(4-methylpiperidin-1-yl)partheno 
lide”) and MAPT. Parthenolide and its derivatives inhibited 
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cellular proliferation in a dose dependent manner betWeen 2 
and 10 uM With 70% inhibition at 10 uM in A549, 50% in 
H460, 40% in H-23 and 40% in H522 (FIG. 2). 
The breast cancer cell line clonogenic assay With hbl-100, 
mdl-231 and 436 cells shoWed almost complete inhibition of 
proliferation With DMAPT at 2 um concentration. Similarly, 
parthenolide reduced proliferation With similar dosage 
ranges (FIG. 3). 
We claim: 
1. A compound of the formula: 
NRIRZ 
wherein: 
R1 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, 
alkenyl, substituted alkenyl, alkynyl, or substituted 
alkynyl; and 
R2 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, 
alkenyl, substituted alkenyl, alkynyl, or substituted 
alkynyl; or 
R1 and R2 are together 4CH2(CH2)nCH2i Where n is 0 
to 5; and together With N form an optionally substituted 
ring, said ring optionally fused to a cycloalkyl or aryl 
group to form a bicyclic or tricyclic system, said system 
optionally substituted and optionally comprising one or 
more heteroatoms; or 
R1 and R2 are together 4CH2(CH2)nCH2Z-; Where Z is 
O, S, Se, Si, P, %Oi, iSOi, iSOzi, or 
iPOi; and n is 0 to 5; and together With N form an 
optionally substituted ring, said ring optionally fused to 
a cycloalkyl or aryl group to form a bicyclic or tricyclic 
ring system, said system optionally substituted and 
optionally comprising one or more heteroatoms; or 
R1 and R2are together iCH2-Z-(CH)bi; Where Z is O, 
S, Se, Si, P, %Oi, iSOi, iSOzi, or iPOi; 
and a and b are independently 1 to 4; and together With 
N form an optionally substituted ring, said ring option 
ally fused to a cycloalkyl or aryl group to form a 
bicyclic or tricyclic ring system, said system optionally 
substituted and optionally comprising one or more 
heteroatoms; or 
a pharmaceutically acceptable salt thereof. 
2. The compound of claim 1 wherein R1 is hydrogen or 
optionally substituted loWer alkyl; and R2 is optionally 
substituted loWer alkyl. 
3. The compound of claim 2 wherein R1 is methyl, ethyl, 
propyl or isobutyl. 
4. The compound of claim 3 Wherein R2 is methyl or 
ethyl. 
5. The compound of claim 1 wherein R1 and R2 are 
4CH2(CH2)nCH2i Where n is 0 to 5; and together With N 
form an optionally substituted ring, said ring optionally 
fused to a cycloalkyl or aryl group to form a bicyclic or 
tricyclic system, said system optionally substituted and 
optionally comprising one or more heteroatoms. 
6. The compound of claim 1 wherein R1 and R2 are 
4CH2(CH2)nCH2Z-; Where Z is O, S, Se, Si, P, 4COi, 
iSOi, iSOzi, or iPOi; and n is 0 to 5; and together 
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With N form an optionally substituted ring, said ring option 
ally fused to a cycloalkyl or aryl group to form a bicyclic or 
tricyclic ring system, said system optionally substituted and 
optionally comprising one or more heteroatoms. 
7. The compound of claim 1 wherein R1 and R2 are 
i(CH2)a-Z-(CH2)bi; Where Z is O, S, Se, Si, P, iCOi, 
Oi, isozi, or iPOi; and a and b are indepen 
dently 1 to 4; and together With N form an optionally 
substituted ring, said ring optionally fused to a cycloalkyl or 
aryl group to form a bicyclic or tricyclic ring system, said 
system optionally substituted and optionally comprising one 
or more heteroatoms. 
8. The compound of claim 1 Wherein NRlR2 form a ring 
selected from optionally substituted aZiridin-1-yl, aZetidin 
1 -yl, pyrrolidin- 1 -yl, piperidin-l -yl, homopiperidyn-l -yl 
and heptamethyleneimin- 1 -yl. 
9. The compound of claim 1: 
11 [3H, 13-Dimethylaminoparthenolide; 
11 [3H, 13-Diethylaminoparthenolide; 
11 [3H, 13-(tert-Butylamino)parthenolide; 
11[3H, 13-(Pyrrolidin-l-yl)parthenolide; 
11 [3H, 13-(Piperidin- 1 -yl)parthenolide; 
11 [3H, l3-(Morpholin-1-yl)parthenolide; 
11 [3H, 13-(4-Methylpiperidin-1-yl)parthenolide; 
11 [3H, 13-(4-MethylpiperaZin-1-yl)parthenolide; 
11[3H, l3-(Homopiperidin-1-yl)parthenolide; 
11 [3H, 13-(Heptamethyleneimin-1-yl)parthenolide; 
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11[3H, 13-(AZetidin-1-yl)parthenolide; or 
11[3H, 13-Diallylaminoparthenolide. 
10. The compound of claim 1: 
11[3H, 13-Dimethylaminoparthenolide hydrochloride; 
1 16H, 13-(Pyrrolidin-l-yl)parthenolide hydrochloride; 
11[3H, l3-(Piperidin-1-yl)parthenolide hydrochloride; 
1 16H, l3-(4-Methylpiperidin-1 -yl)parthenolide hydro 
chloride; 
11[3H, 13-Dimethylaminoparthenolide maleate; 
11[3H, 13-Dimethylaminoparthenolide methiodide; or 
11[3H, l3-(4-Methylpiperidin-1-yl)parthenolide methio 
dide. 
11. A pharmaceutical composition comprising a com 
pound of claim 1 or a pharmaceutically acceptable salt 
thereof in combination With a pharmaceutically e?cective 
diluent or carrier. 
12. A method of inhibiting cancer cell groWth, comprising 
contacting said cells With an amount of a compound of claim 
1 effective to inhibit the groWth of said cancer cells. 
13. The compound of claim 9: llotH, 13-Dimethylami 
noparthenolide. 
14. The composition of claim 11 Wherein the compound 
is 11(XH, 13-Dimethylaminoparthenolide. 
15. The method of claim 12 Wherein the compound is 
llotH, 13 -Dimethylaminoparthenolide. 
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